Literature DB >> 29099418

Temozolomide treatment of a malignant pheochromocytoma and an unresectable MAX-related paraganglioma.

Alfonso M Ferrara1, Giuseppe Lombardi2, Ardi Pambuku2, Domenico Meringolo3, Roberta Bertorelle4, Margherita Nardin5, Francesca Schiavi1, Maurizio Iacobone6, Giuseppe Opocher7, Vittorina Zagonel2, Stefania Zovato1.   

Abstract

Pheochromocytomas (PCCs) and paragangliomas (PGLs) are neuroendocrine tumors with a strong genetic background. The mainstay of treatment for PCC/PGLs is surgery. However, for unresectable lesions, no curative treatment is currently available. Temozolomide (TMZ) has been shown to determine radiological and biochemical response in malignant PCC/PGLs. We report two cases of PCC/PGLs treated with TMZ. Case 1 is a 51-year-old man with local and distant recurrence (liver and bone metastases) of right adrenal PCC. Case 2 is a 54-year-old woman with a PCC/PGL syndrome caused by a mutation in MAX gene (c.171+1G>A), operated on for bilateral adrenal PCC and presenting with a large unresectable abdominal PGL. Both patients presented hypertension due to catecholamine hypersecretion. TMZ determined radiological response according to RECIST criteria, reduction of urinary catecholamine levels, and controlled hypertension in both patients. Furthermore, the current study demonstrates, for the first time, that MAX-related PGLs are responsive to TMZ.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29099418     DOI: 10.1097/CAD.0000000000000570

Source DB:  PubMed          Journal:  Anticancer Drugs        ISSN: 0959-4973            Impact factor:   2.248


  4 in total

Review 1.  Overview of the 2022 WHO Classification of Familial Endocrine Tumor Syndromes.

Authors:  Vania Nosé; Anthony Gill; José Manuel Cameselle Teijeiro; Aurel Perren; Lori Erickson
Journal:  Endocr Pathol       Date:  2022-03-13       Impact factor: 3.943

Review 2.  Temozolomide Is a Potential Therapeutic Tool for Patients With Metastatic Pheochromocytoma/Paraganglioma-Case Report and Review of the Literature.

Authors:  Anli Tong; Ming Li; Yunying Cui; Xiaosen Ma; Huiping Wang; Yuxiu Li
Journal:  Front Endocrinol (Lausanne)       Date:  2020-02-18       Impact factor: 5.555

Review 3.  Metastatic Pheochromocytomas and Abdominal Paragangliomas.

Authors:  Dan Granberg; Carl Christofer Juhlin; Henrik Falhammar
Journal:  J Clin Endocrinol Metab       Date:  2021-04-23       Impact factor: 5.958

4.  Sunitinib Treatment for Advanced Paraganglioma: Case Report of a Novel SDHD Gene Mutation Variant and Systematic Review of the Literature.

Authors:  Franz Sesti; Tiziana Feola; Giulia Puliani; Roberta Centello; Valentina Di Vito; Oreste Bagni; Andrea Lenzi; Andrea M Isidori; Vito Cantisani; Antongiulio Faggiano; Elisa Giannetta
Journal:  Front Oncol       Date:  2021-06-17       Impact factor: 6.244

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.